Skip to main content
. 2017 Mar 9;17:202. doi: 10.1186/s12879-017-2303-2

Table 3.

Antibiotic management of ADI

OPAT ADI (n = 110)a
Antibiotic Management
 Received Pre-ED/UC PO antibiotics – n (%) 49 (45)
 Days of OPAT IV - median (IQR) 3 [2]
 Days of Post-OPAT PO – median (IQR) 9 [3]
 Total OPAT & Post-OPAT days – median (IQR) 15 [4]
Antibiotic Regime – n (%)
ED/UC prescription (IV) (n = 105)
 Cefazolin & metronidazoleb 60 (57)
 Clindamycinc 22 [21]
 Ceftriaxone & metronidazoleb 13 [12]
 Other 10 [10]
OPAT prescription (IV) (n = 108)
 Cefazolin & metronidazoleb 84 (78)
 Ceftriaxone & metronidazoleb 14 [13]
 Clindamycinc 10 [9]
OPAT discharge prescription (PO) (n = 107)
 Cephalexin or cefadroxil both with metronidazole 64 (60)
 Amoxicillin-clavulanic acid 24 [22]
 Clindamycinc 16 [15]
 Other 3 [3]
Regime Specific Duration of Antibiotics – days
 Parenteral (IV)g p = 0.2
 Narrow spectrum IV regime – mean (SD)d 4.2 (2.2)
 Broad spectrum IV regime – mean (SD)e 3.2 (1.1)
 Total course (IV & PO) (n = 107) p = 0.4
 Narrow spectrum regimef – mean (SD) 14.9 (4.3)
 Broad spectrum regime# – mean (SD) 15.2 (5.4)

ED emergency department, UC urgent care, IV intravenous, PO oral route, IQR interquartile range, SD standard deviation

an = 110 unless otherwise specified

bMetronidazole component in either PO or IV formulation

cOf those receiving clindamycin 5 had clinical record of a beta-lactam allergy

dNarrow spectrum IV regime = cefazolin or penicillin both with metronidazole, PO regime = amoxicillin or cephalexin or cefadroxil with metronidazole

eBroad spectrum IV regime = clindamycin alone or ceftriaxone with metronidazole, PO regime = amoxicillin-clavulanic acid or clindamycin

fDefined as majority of days of treatment consisting of either broad or narrow spectrum agents

gExcluding cases where only a single initial dose of ceftriaxone was given and participants were then discharged on oral antibiotics